News
Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback